Copyright Reports & Markets. All rights reserved.

Global Patient Derived Xenograft/PDX Models Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Patient Derived Xenograft/PDX Models Revenue
  • 1.4 Market by Type
    • 1.4.1 Global Patient Derived Xenograft/PDX Models Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Gastrointestinal Tumor Models
    • 1.4.3 Gynecological Tumor Models
    • 1.4.4 Respiratory Tumor Models
    • 1.4.5 Urological Tumor Models
    • 1.4.6 Hematological Tumor Models
  • 1.5 Market by Application
    • 1.5.1 Global Patient Derived Xenograft/PDX Models Market Share by Application: 2020 VS 2026
    • 1.5.2 Pre-clinical Drug Development and Basic Cancer Research
    • 1.5.3 Biomarker Analysis
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends

  • 2.1 Global Patient Derived Xenograft/PDX Models Market Perspective (2015-2026)
  • 2.2 Global Patient Derived Xenograft/PDX Models Growth Trends by Regions
    • 2.2.1 Patient Derived Xenograft/PDX Models Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Patient Derived Xenograft/PDX Models Historic Market Share by Regions (2015-2020)
    • 2.2.3 Patient Derived Xenograft/PDX Models Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Patient Derived Xenograft/PDX Models Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Patient Derived Xenograft/PDX Models Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Patient Derived Xenograft/PDX Models Players by Market Size
    • 3.1.1 Global Top Patient Derived Xenograft/PDX Models Players by Revenue (2015-2020)
    • 3.1.2 Global Patient Derived Xenograft/PDX Models Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Patient Derived Xenograft/PDX Models Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Patient Derived Xenograft/PDX Models Market Concentration Ratio
    • 3.2.1 Global Patient Derived Xenograft/PDX Models Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Patient Derived Xenograft/PDX Models Revenue in 2019
  • 3.3 Patient Derived Xenograft/PDX Models Key Players Head office and Area Served
  • 3.4 Key Players Patient Derived Xenograft/PDX Models Product Solution and Service
  • 3.5 Date of Enter into Patient Derived Xenograft/PDX Models Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type (2015-2026)

  • 4.1 Global Patient Derived Xenograft/PDX Models Historic Market Size by Type (2015-2020)
  • 4.2 Global Patient Derived Xenograft/PDX Models Forecasted Market Size by Type (2021-2026)

5 Market Size by Application (2015-2026)

  • 5.1 Global Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)
  • 5.2 Global Patient Derived Xenograft/PDX Models Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Patient Derived Xenograft/PDX Models Market Size (2015-2020)
  • 6.2 Patient Derived Xenograft/PDX Models Key Players in North America (2019-2020)
  • 6.3 North America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
  • 6.4 North America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Patient Derived Xenograft/PDX Models Market Size (2015-2020)
  • 7.2 Patient Derived Xenograft/PDX Models Key Players in Europe (2019-2020)
  • 7.3 Europe Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
  • 7.4 Europe Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

8 China

  • 8.1 China Patient Derived Xenograft/PDX Models Market Size (2015-2020)
  • 8.2 Patient Derived Xenograft/PDX Models Key Players in China (2019-2020)
  • 8.3 China Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
  • 8.4 China Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

9 Japan

  • 9.1 Japan Patient Derived Xenograft/PDX Models Market Size (2015-2020)
  • 9.2 Patient Derived Xenograft/PDX Models Key Players in Japan (2019-2020)
  • 9.3 Japan Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
  • 9.4 Japan Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

10 Southeast Asia

  • 10.1 Southeast Asia Patient Derived Xenograft/PDX Models Market Size (2015-2020)
  • 10.2 Patient Derived Xenograft/PDX Models Key Players in Southeast Asia (2019-2020)
  • 10.3 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
  • 10.4 Southeast Asia Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

11 India

  • 11.1 India Patient Derived Xenograft/PDX Models Market Size (2015-2020)
  • 11.2 Patient Derived Xenograft/PDX Models Key Players in India (2019-2020)
  • 11.3 India Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
  • 11.4 India Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

12 Central & South America

  • 12.1 Central & South America Patient Derived Xenograft/PDX Models Market Size (2015-2020)
  • 12.2 Patient Derived Xenograft/PDX Models Key Players in Central & South America (2019-2020)
  • 12.3 Central & South America Patient Derived Xenograft/PDX Models Market Size by Type (2015-2020)
  • 12.4 Central & South America Patient Derived Xenograft/PDX Models Market Size by Application (2015-2020)

13 Key Players Profiles

  • 13.1 Crown Bioscience
    • 13.1.1 Crown Bioscience Company Details
    • 13.1.2 Crown Bioscience Business Overview
    • 13.1.3 Crown Bioscience Patient Derived Xenograft/PDX Models Introduction
    • 13.1.4 Crown Bioscience Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020))
    • 13.1.5 Crown Bioscience Recent Development
  • 13.2 The Jackson Laboratory
    • 13.2.1 The Jackson Laboratory Company Details
    • 13.2.2 The Jackson Laboratory Business Overview
    • 13.2.3 The Jackson Laboratory Patient Derived Xenograft/PDX Models Introduction
    • 13.2.4 The Jackson Laboratory Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.2.5 The Jackson Laboratory Recent Development
  • 13.3 Champions Oncology
    • 13.3.1 Champions Oncology Company Details
    • 13.3.2 Champions Oncology Business Overview
    • 13.3.3 Champions Oncology Patient Derived Xenograft/PDX Models Introduction
    • 13.3.4 Champions Oncology Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.3.5 Champions Oncology Recent Development
  • 13.4 Charles River Laboratories
    • 13.4.1 Charles River Laboratories Company Details
    • 13.4.2 Charles River Laboratories Business Overview
    • 13.4.3 Charles River Laboratories Patient Derived Xenograft/PDX Models Introduction
    • 13.4.4 Charles River Laboratories Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.4.5 Charles River Laboratories Recent Development
  • 13.5 WuXi Apptec
    • 13.5.1 WuXi Apptec Company Details
    • 13.5.2 WuXi Apptec Business Overview
    • 13.5.3 WuXi Apptec Patient Derived Xenograft/PDX Models Introduction
    • 13.5.4 WuXi Apptec Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.5.5 WuXi Apptec Recent Development
  • 13.6 Oncodesign
    • 13.6.1 Oncodesign Company Details
    • 13.6.2 Oncodesign Business Overview
    • 13.6.3 Oncodesign Patient Derived Xenograft/PDX Models Introduction
    • 13.6.4 Oncodesign Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.6.5 Oncodesign Recent Development
  • 13.7 Horizon Discovery
    • 13.7.1 Horizon Discovery Company Details
    • 13.7.2 Horizon Discovery Business Overview
    • 13.7.3 Horizon Discovery Patient Derived Xenograft/PDX Models Introduction
    • 13.7.4 Horizon Discovery Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.7.5 Horizon Discovery Recent Development
  • 13.8 Pharmatest Services
    • 13.8.1 Pharmatest Services Company Details
    • 13.8.2 Pharmatest Services Business Overview
    • 13.8.3 Pharmatest Services Patient Derived Xenograft/PDX Models Introduction
    • 13.8.4 Pharmatest Services Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.8.5 Pharmatest Services Recent Development
  • 13.9 Hera Biolabs
    • 13.9.1 Hera Biolabs Company Details
    • 13.9.2 Hera Biolabs Business Overview
    • 13.9.3 Hera Biolabs Patient Derived Xenograft/PDX Models Introduction
    • 13.9.4 Hera Biolabs Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.9.5 Hera Biolabs Recent Development
  • 13.10 EPO Berlin-Buch
    • 13.10.1 EPO Berlin-Buch Company Details
    • 13.10.2 EPO Berlin-Buch Business Overview
    • 13.10.3 EPO Berlin-Buch Patient Derived Xenograft/PDX Models Introduction
    • 13.10.4 EPO Berlin-Buch Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 13.10.5 EPO Berlin-Buch Recent Development
  • 13.11 Xentech
    • 10.11.1 Xentech Company Details
    • 10.11.2 Xentech Business Overview
    • 10.11.3 Xentech Patient Derived Xenograft/PDX Models Introduction
    • 10.11.4 Xentech Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 10.11.5 Xentech Recent Development
  • 13.12 Urolead
    • 10.12.1 Urolead Company Details
    • 10.12.2 Urolead Business Overview
    • 10.12.3 Urolead Patient Derived Xenograft/PDX Models Introduction
    • 10.12.4 Urolead Revenue in Patient Derived Xenograft/PDX Models Business (2015-2020)
    • 10.12.5 Urolead Recent Development

14 Analyst's Viewpoints/Conclusions

    15 Appendix

    • 15.1 Research Methodology
      • 15.1.1 Methodology/Research Approach
      • 15.1.2 Data Source
    • 15.2 Disclaimer

    Patient Derived Xenograft/PDX Models market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Patient Derived Xenograft/PDX Models market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

    The key players covered in this study
    Crown Bioscience
    The Jackson Laboratory
    Champions Oncology
    Charles River Laboratories
    WuXi Apptec
    Oncodesign
    Horizon Discovery
    Pharmatest Services
    Hera Biolabs
    EPO Berlin-Buch
    Xentech
    Urolead

    Market segment by Type, the product can be split into
    Gastrointestinal Tumor Models
    Gynecological Tumor Models
    Respiratory Tumor Models
    Urological Tumor Models
    Hematological Tumor Models
    Market segment by Application, split into
    Pre-clinical Drug Development and Basic Cancer Research
    Biomarker Analysis

    Market segment by Regions/Countries, this report covers
    North America
    Europe
    China
    Japan
    Southeast Asia
    India
    Central & South America

    Buy now